Besides the role in supporting viral replication, MAPK3 hyperactivation can trigger inflammation (e.g., IL-6, TNF-α) and lung epithelial damage, central to severe COVID-19 [72], and today, MAPK pathway inhibitors are under investigation to mitigate inflammation and viral replication [72]. Here, IL6 is linked to COVID-19.